Genix Pharmaceuticals Corporation
GENX.V
TSX
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -72.77% | 104.06% | 51.22% | 63.37% | 74.05% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -99.80% |
| Total Amortization of Deferred Charges | -- | -75.00% | -- | -- | -- |
| Total Other Non-Cash Items | 194.74% | -106.33% | 1,163.16% | 175.00% | 2,750.00% |
| Change in Net Operating Assets | -566.67% | 77.10% | 110.78% | -119.72% | -97.80% |
| Cash from Operations | -40.95% | 33.63% | 15.40% | -4.61% | 17.54% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 36.32% | -33.86% | 179.04% | 3.16% | -72.33% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 29.53% | -39.00% | 172.00% | 6.91% | -51.86% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -241.18% | -83.33% | 101.85% | 128.57% | -107.14% |